The integrase strand transfer inhibitors (INSTIs) bictegravir (BIC), dolutegravir (DTG), and cabotegravir (CAB) have improved resistance profiles when compared to raltegravir and elvitegravir (EVG), with few reported cases of resistance in the clinic. This study used in vitro drug selections with primary HIV-1 isolates to examine potential pathways for resistance to EVG and DTG and the investigational drugs BIC and CAB.
Subtype B (n=7) and non-B subtypes (n=5) strains were amplified from PBMCs of primary HIV infections through co-culture in cord blood mononuclear cells (CBMCs). CBMCs were serially passaged in escalating concentrations of DTG, EVG, BIC, and/or CAB for 36-46 weeks. Sanger and ultradeep sequencing ascertained the acquisition of resistance mutations under selective drug pressure at weeks 8-9, 16, 24-30, and 43-46.
Parallel in vitro selections found resistance mutations in more strains for EVG (12/12), followed by CAB (8/12), and BIC and DTG (6/12 each). For EVG, T66I (n=8), E92 G/V/Q (n=3) or R263K (n=1) were followed by the accumulation of mutations leading to viral escape and high-level resistance (bold). With CAB, at the final passages, 8/12 selections resulted in R263K (n=3), Q148K, S153Y, or S147G with acquisition of Q148R/K in two strains leading to viral escape. For DTG and BIC at the final passages, 6/12 strains had singleton mutations R263K, S153Y or H51Y which conferred low-level (<3-fold) resistance and reduced replicative fitness, precluding escalations in DTG and BIC beyond 5-25 nM.
There is a high genetic barrier to resistance to BIC and DTG compared to CAB and EVG. Emergent resistance mutations by singleton mutations, R263K or S153Y confers <1.5-3 resistance retaining antiviral activity to DTG and BIC, whereas more complicated patterns of high-level resistance were selected by CAB and EVG. Ongoing studies will deduce resistance to INSTIs in larger panel of viral strains.